Stemcells, Inc. Form 8-K
Table of Contents



SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K

CURRENT REPORT
Pursuant to
Section 13 or 15(d) of

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): November 11, 2003


STEMCELLS, INC.

(Exact name of registrant as specified in its charter)
         
Delaware   0-19871   94-3078125
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (I.R.S. Employer
Identification Number)

3155 Porter Drive
Palo Alto, California 94304

(Address, of principal executive offices, including zip code)

(650) 475-3100

(Registrant’s Telephone number including area code)




 


TABLE OF CONTENTS

Item 5. OTHER EVENTS
SIGNATURES
EXHIBIT INDEX
EXHIBIT 99.1


Table of Contents

Item 5. OTHER EVENTS

On November 11, 2003, StemCells, Inc. (the “Company”) reported that Riverview Group, LLC (“Riverview”) exercised its right to convert the remaining shares of the Company’s 3% Convertible Preferred stock held by Riverview. Riverview will receive 1,010,833 shares of the Company’s common stock upon conversion of these shares of the Company’s 3% Convertible Preferred Stock, including shares of common stock issued with respect to accrued and unpaid dividends.

In addition, on November 11, 2003 the Company reported that Riverview exercised a warrant to purchase shares of the Company’s common stock. This warrant entitles Riverview to purchase up to 1,898,000 shares of the Company’s common stock on the terms set forth in the warrant at a price of $1.50 per share. Riverview exercised the warrant with respect to 1,098,000 shares of common stock and the Company will receive an aggregate exercise price of $1,647,000. The warrant will remain exercisable for 800,000 shares of the Company’s common stock in accordance with the terms of the warrant.

A copy of the Company’s press release announcing the transactions described above is attached as Exhibit 99.1 to this Report and is incorporated in this Report by reference.

-2-


Table of Contents

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    STEMCELLS, INC
         
    By:   /s/ Martin McGlynn
       
        Martin McGlynn
President and Chief Executive Officer
Date: November 11, 2003        

-3-


Table of Contents

EXHIBIT INDEX

                            99.1                   Press release issued by StemCells, Inc. on November 11, 2003.

-4-